CM
ASND icon

Capula Management’s Ascendis Pharma A/S ASND Stock Holding History

Capula Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,669
Closed -$945K – 485
2020
Q4 		$945K Buy
+5,669
New +$937K 0.05% 212

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Capula Management's ASND Position: Q1 2021 in Review

Capula Management sold out of Ascendis Pharma A/S (ASND) in Q1 2021, closing a stake of 5,669 shares — an estimated $945K sold.

Capula Management first reported a position in ASND in Q4 2020 and held it in 1 quarter. The position peaked at $945K in Q4 2020. 177 funds tracked by Wall St. Rank hold ASND as of Q1 2021.

  • Capula Management reported no remaining Ascendis Pharma A/S position as of Q1 2021 after selling out during the quarter.
  • Capula Management sold 5,669 Ascendis Pharma A/S shares in Q1 2021, an estimated $945K.
  • Capula Management first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 1 quarter.
  • Capula Management's Ascendis Pharma A/S position peaked at $945K in Q4 2020.
  • 177 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2021.

Based on Capula Management's 13F filing for Q1 2021, filed 14 May 2021.